Month: April 2020

MTBC and CareCloud Release Initial Findings from New COVID-19 Practice Impact Survey and Operational DataSOMERSET, N.J., April 13, 2020 (GLOBE NEWSWIRE) — MTBC, Inc. (Nasdaq: MTBC) (Nasdaq: MTBCP), a leading provider of cloud-based healthcare IT solutions and services, including telehealth, is helping medical groups stay informed and quickly address those areas posing the biggest risk to their practices during the COVID-19 pandemic. Initial findings show that practices are most focused on staying in close contact with patients, migrating in-office visits to telehealth and protecting patients and staff from infection.MTBC and CareCloud’s COVID-19 Practice Pulse provides a current snapshot of physician concerns and actions they are taking during the pandemic. Through a combination of medical practice operations data and surveying...

NEW YORK, April 13, 2020 (GLOBE NEWSWIRE) — Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) announced today that it will release results for its first quarter ended March 29, 2020 on Thursday, April 30, 2020 after the market close. The Company will host a conference call on Friday, May 1, 2020 at 11:00 a.m. Eastern Time to discuss these results.The conference call will be webcast and can be accessed at Minerals Technologies’ website at www.mineralstech.com. To listen to the call, go to the MTI website and click on “Investor Relations,” then click on “Quarterly Results & Conference Calls.”About Minerals Technologies Inc.New York-based Minerals Technologies Inc. (MTI) is a resource- and technology-based growth company that develops, produces and markets worldwide a broad range of specialty...

FREMONT, CA, April 13, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS and ophthalmology, today announced it had entered into two financial transactions that will improve working capital while reducing debt, and support the funding of drug development programs and ongoing clinical trials.American BriVision said that three holders of convertible promissory notes with a 20% discount, issued on January 21, 2020, and representing an aggregate principal amount of $800,000 plus accrued interest expenses, have entered into exchange agreements with the company on April 5, 2020. Pursuant to the agreements, the holders have exchanged their notes at an exchange price of $1.84 per share for...

ENGLEWOOD, Colo., April 13, 2020 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) announced that Dr. Patrick R. Gruber, Chief Executive Officer of Gevo, Inc., will participate and present in the alphaDIRECT Advisors Virtual Conference Series on April 14, 2020, at 12:00 pm EDT / 10:00 am MDT as part of the alphaDIRECT Investor Intelligence Program.Dr. Gruber will present on Gevo’s Low Carbon, Clean Fuels followed by a question and answer session. The presentation will be webcast live and available for replay under the Investor Relations page found on www.gevo.com and under alphaDIRECT Advisors center page at www.alphadirectadvisors.com.Registration Link:https://globalmeet.webcasts.com/starthere.jsp?ei=1304371&tp_key=9b5624f4c0About GevoGevo is commercializing the next generation of jet fuel, gasoline and diesel fuel with the potential...

NEW YORK, NY, April 13, 2020 (GLOBE NEWSWIRE) — PharmaCyte Biotech (OTCQB: PMCB) is a California-based biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, and while it continues to focus on submitting an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for its treatment for locally advanced, inoperable pancreatic cancer, it has also seized an opportunity to offer testing kits for the coronavirus disease (COVID-19).  According to the company’s investor relations, this opportunity would create a revenue stream for its pancreatic cancer program.The virus—known as “Severe Acute Respiratory Syndrome Coronavirus 2” or “SARS-CoV-2,” causes the disease COVID-19, which has become a global pandemic...

-To Provide Clinical Development Update on CAP-1002--Final HOPE-2 Data Now Expected by Mid-Q2-LOS ANGELES, April 13, 2020 (GLOBE NEWSWIRE) —  Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment or prevention of serious diseases, today announced that it will host a Key Opinion Leader (KOL) call on the cardiac complications of DMD on Wednesday, April 15, 2020 at 1:30 pm Eastern Time.The call will feature a presentation by key opinion leader Michael Taylor, M.D., Ph.D. (Cincinnati Children’s Hospital), Director of Advanced Imaging Innovation. Dr. Taylor will provide an overview of Duchenne muscular dystrophy, particularly focusing on the cardiac complications of the disease, its progression and current cardiac treatment...

CALGARY, Alberta, April 13, 2020 (GLOBE NEWSWIRE) — Canoe Financial LP today announced the launch of Canoe Defensive Global Balanced Fund, an actively managed solution that will offer investors innovative and proven downside protection while maintaining the ability to generate returns in up markets.The Fund will include investment strategies managed by three award-winning portfolio management teams: Canoe Financial, Fiera Capital Corporation, and Aegon USA Investment Management, LLC.“Canoe Defensive Global Balanced Fund will have the capability to protect against stock market volatility beyond the traditional balanced funds in the industry,” said Darcy Hulston, President and CEO of Canoe Financial. Nadim Rizk and the Global Equity Team from Fiera Capital will manage the equity allocation of the portfolio.  It will include the proprietary...

GRAND CAYMAN, Cayman Islands, April 13, 2020 (GLOBE NEWSWIRE) — Greenlight Capital Re, Ltd. (NASDAQ: GLRE) (“Greenlight Re” or the “Company”), a global specialty property and casualty reinsurer headquartered in the Cayman Islands, today announced preliminary, unaudited financial estimates of its results of operations for the quarter ended March 31, 2020.On a preliminary estimated basis:The Company expects its results of operations for the quarter ended March 31, 2020 to reflect:A net loss of $38 million to $43 million or ($1.05) to ($1.19) per fully diluted share.Net premiums written of $107 million to $112 millionNet premiums earned of $109 million to $114 millionAn underwriting loss of $1 million to an underwriting gain of $4 millionA composite ratio of 96% to 100%A combined ratio of 97% to 101%An investment loss in the Solasglas...

– Company Ramping Up WatchPAT™ ONE Production Capacity to Meet Demand for Disposable Home Sleep Apnea Tests –